期刊文献+

滋和汤化裁分期治疗月经过少随机对照研究 被引量:3

Randomized Controlled Study on Modified Zihe Decoction Treating Scanty Menstruation by Stages
下载PDF
导出
摘要 目的:探讨滋和汤化裁分期治疗月经过少的临床价值。方法:采用随机对照研究方法,将合格受试者按1∶1比例随机分为试验组和对照组,分别给予滋和汤化裁分期治疗及戊酸雌二醇治疗,观察治疗前后患者月经量、经期及子宫内膜厚度的变化,对其疗效进行评价。结果:试验组的愈显率和总有效率分别为76.67%和86.67%,对照组的愈显率和总有效率分别为40.00%和73.33%,两组间疗效差异有统计学意义(P<0.05)。两组患者治疗后子宫内膜厚度均得到改善,每组治疗前后差异存在统计学意义(P<0.05)。结论:滋和汤化裁分期治疗月经过少有较好临床疗效。 Objective : To explore the clinical value of Zihe Decoction treating scanty menstruation by stages. Methods : Using the randomized controlled method, we divided the eligible subjects into experimental group and control group by the proportion of 1 : 1 and then treated those two groups with modified Zihe Decoction and estradiol valerate respectively and observed the changes of patients' menstrual quantity, menstruation and endometrial thickness before and after treatment. Lastly we evaluated their curative effect. Results : The experimental group's cure rate and significant efficiency rate were 76.67% and 86.67% and in turn, those of the control group were 40.00% and 73.33%. The difference was statistically significant between two groups ( P〈0.05 ). After the treatment, two groups patients' endometrial thickness were ameliorated and their difference was statistically significant (P〈0.05). Conclusion: Modified Zihe Decoction has a good curative effect in treating scanty menstruation by stages.
出处 《辽宁中医药大学学报》 CAS 2015年第5期11-13,共3页 Journal of Liaoning University of Traditional Chinese Medicine
基金 国家中医药管理局2010年全国名老中医药专家传承工作室建设项目
关键词 月经过少 滋和汤 中医药疗法 scanty menstruation Zihe Decoction traditional Chinese medicine therapy
  • 相关文献

参考文献2

二级参考文献8

  • 1Jabbour HN,Kelly RW,Fraser HM,et al.Endocrine regulation of menstruation[J].Endocr Rew,2006; 27(1):17-46.
  • 2Wagatsuma A,Tamaki H,Ogita F.Sequential expression of vascular endothelial growth factor,Flt -1,and KDR/Flk -1 in regenerating mouse skeletal muscle[J].Physiol Res,2006;[Epub ahead of print].
  • 3Herve MA,Medyri G.Regulation of the vascular endothelial growth factor(VEGF)receptor Flk-1/KDR by estradiol through VEGF in uterus[J].J Endicrinol,2006; 188(1):91-99.
  • 4Hyder SM,Nawaz Z,Chiappetta C,et al.Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor[J].Cancer Research,2000;60(12):3183-3190.
  • 5Buteau-Lozano F.Transcriptional Regulation of Vascular Endothelial Growth Factor by Estradiol and Tamoxifen in Breast Cancer Cells A Complex Interplay between Estrogen Receptors and β[J].Cancer Research,2002; 62(17):4977-4984.
  • 6Stoner M,Wormke M,Saville B,et al.Estrogen regulation of vascular endothelial growth factor gene expressionin ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins[J].Oncogene,2004; 23(5):1052 1063.
  • 7Koos RD,KaziAA.New insight into the transcriptional regulation of vascular endothelial growth factor expression in the endometrium by estrogen and relaxin[J].Ann N Y Acad Sci,2005;1041:233-247.
  • 8Koduri S,Goldhar AS,Vonderhaar BK.Activation of vascular endothelial growth factor(VEGF)by the ER-alpha variant,ER Delta3[J].Breast Cancer Res Treat,2006; 95(1):37-43.

共引文献152

同被引文献99

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部